Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-41,800
Closed -$1.01M – 10441
2025
Q3
$1.01M Hold
41,800
– – ﹤0.01% 5567
2025
Q2
$813K Buy
+41,800
New +$618K ﹤0.01% 5615
2021
Q1
– Sell
-80,000
Closed -$2.78M – 8925
2020
Q4
$2.78M Buy
80,000
+40,000
+100% +$1.13M ﹤0.01% 3066
2020
Q3
$693K Hold
40,000
– – ﹤0.01% 3916
2020
Q2
$657K Hold
40,000
– – ﹤0.01% 3913
2020
Q1
$363K Buy
40,000
+32,500
+433% +$655K ﹤0.01% 4252
2019
Q4
$159K Sell
7,500
-123,200
-94% -$2.73M ﹤0.01% 5739
2019
Q3
$3M Buy
130,700
+50,000
+62% +$1.14M ﹤0.01% 2890
2019
Q2
$1.96M Buy
+80,700
New +$1.66M ﹤0.01% 3167

Other funds holding ADNT

UBS Group's ADNT Position: Q3 2026 in Review

UBS Group reduced its Adient (ADNT) stake by 4.9% in Q3 2026, selling an estimated $1.62M and leaving 1,619,475 shares worth $27.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2325.

UBS Group first reported a position in ADNT in Q4 2016 and has held it in 40 quarters since. The position peaked at $77.2M in Q1 2018. 304 funds tracked by Wall St. Rank hold ADNT as of Q3 2026.

  • UBS Group held 1,619,475 shares of Adient worth $27.3M as of Q3 2026.
  • UBS Group sold 83,878 Adient shares in Q3 2026, an estimated $1.62M.
  • Adient made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #2325 holding.
  • UBS Group first reported a position in Adient in Q4 2016 and has held it in 40 quarters since.
  • UBS Group's Adient position peaked at $77.2M in Q1 2018.
  • 304 funds tracked by Wall St. Rank held Adient as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.